| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterocolitis, Necrotizing | 26 | 2024 | 248 | 9.950 |
Why?
|
| Sepsis | 22 | 2025 | 516 | 7.890 |
Why?
|
| Infant, Premature | 42 | 2024 | 859 | 6.100 |
Why?
|
| Infant, Premature, Diseases | 14 | 2024 | 255 | 4.780 |
Why?
|
| Lactoferrin | 13 | 2023 | 78 | 4.700 |
Why?
|
| Infant, Newborn | 87 | 2025 | 8576 | 4.280 |
Why?
|
| Probiotics | 8 | 2023 | 229 | 3.060 |
Why?
|
| Neonatal Sepsis | 5 | 2025 | 39 | 2.800 |
Why?
|
| Intensive Care Units, Neonatal | 8 | 2023 | 327 | 2.630 |
Why?
|
| Bronchopulmonary Dysplasia | 6 | 2024 | 210 | 2.490 |
Why?
|
| Microbiota | 6 | 2022 | 442 | 2.320 |
Why?
|
| Enteral Nutrition | 5 | 2020 | 270 | 2.270 |
Why?
|
| Dysbiosis | 7 | 2022 | 145 | 2.110 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2024 | 342 | 1.940 |
Why?
|
| Ductus Arteriosus, Patent | 4 | 2023 | 148 | 1.780 |
Why?
|
| Laryngoscopy | 4 | 2023 | 157 | 1.760 |
Why?
|
| Pentoxifylline | 5 | 2023 | 20 | 1.730 |
Why?
|
| Resuscitation | 7 | 2023 | 269 | 1.630 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2021 | 823 | 1.610 |
Why?
|
| Infant Mortality | 4 | 2024 | 180 | 1.610 |
Why?
|
| Intubation, Intratracheal | 4 | 2023 | 291 | 1.590 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2020 | 1201 | 1.520 |
Why?
|
| Evidence-Based Medicine | 4 | 2025 | 677 | 1.410 |
Why?
|
| Humans | 105 | 2025 | 133849 | 1.400 |
Why?
|
| Precision Medicine | 2 | 2025 | 356 | 1.350 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2025 | 176 | 1.340 |
Why?
|
| Cross Infection | 3 | 2023 | 332 | 1.250 |
Why?
|
| Infant, Very Low Birth Weight | 4 | 2024 | 178 | 1.230 |
Why?
|
| Pediatrics | 4 | 2025 | 1216 | 1.160 |
Why?
|
| Peptide Fragments | 4 | 2024 | 833 | 1.150 |
Why?
|
| Hypertension, Pulmonary | 3 | 2024 | 467 | 1.090 |
Why?
|
| Infant | 24 | 2024 | 13135 | 1.080 |
Why?
|
| Retinopathy of Prematurity | 3 | 2023 | 64 | 1.080 |
Why?
|
| Meta-Analysis as Topic | 2 | 2025 | 172 | 1.060 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2023 | 180 | 1.060 |
Why?
|
| Catheter-Related Infections | 3 | 2020 | 104 | 1.040 |
Why?
|
| Bacteremia | 3 | 2022 | 417 | 1.030 |
Why?
|
| Biofilms | 4 | 2020 | 93 | 1.010 |
Why?
|
| Skin | 2 | 2019 | 551 | 0.950 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2015 | 52 | 0.950 |
Why?
|
| Lung Diseases | 4 | 2023 | 401 | 0.940 |
Why?
|
| Bacterial Infections | 5 | 2020 | 325 | 0.940 |
Why?
|
| Infant, Low Birth Weight | 4 | 2015 | 176 | 0.910 |
Why?
|
| Zika Virus Infection | 2 | 2016 | 175 | 0.880 |
Why?
|
| Staphylococcus epidermidis | 4 | 2013 | 39 | 0.880 |
Why?
|
| Placental Insufficiency | 1 | 2024 | 15 | 0.870 |
Why?
|
| Candidiasis | 5 | 2013 | 138 | 0.870 |
Why?
|
| Prebiotics | 1 | 2023 | 29 | 0.850 |
Why?
|
| Anti-Infective Agents | 4 | 2015 | 269 | 0.820 |
Why?
|
| Immunoglobulins | 3 | 2011 | 176 | 0.810 |
Why?
|
| Administration, Oral | 8 | 2020 | 730 | 0.810 |
Why?
|
| Neonatal Screening | 1 | 2024 | 193 | 0.790 |
Why?
|
| Biomarkers | 6 | 2024 | 3422 | 0.780 |
Why?
|
| Vascular Malformations | 1 | 2024 | 104 | 0.780 |
Why?
|
| Anti-Bacterial Agents | 8 | 2023 | 2515 | 0.780 |
Why?
|
| Leptin | 1 | 2024 | 225 | 0.780 |
Why?
|
| Computer Simulation | 1 | 2025 | 702 | 0.760 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2024 | 244 | 0.750 |
Why?
|
| Sirolimus | 1 | 2024 | 253 | 0.750 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 235 | 0.750 |
Why?
|
| Fetal Growth Retardation | 1 | 2024 | 241 | 0.750 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 1153 | 0.750 |
Why?
|
| C-Reactive Protein | 2 | 2024 | 472 | 0.750 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 2 | 2024 | 410 | 0.740 |
Why?
|
| Sensitivity and Specificity | 6 | 2025 | 2157 | 0.740 |
Why?
|
| Music Therapy | 1 | 2021 | 8 | 0.740 |
Why?
|
| Lung | 3 | 2024 | 1557 | 0.730 |
Why?
|
| Biliary Atresia | 1 | 2024 | 204 | 0.720 |
Why?
|
| Birth Weight | 2 | 2021 | 352 | 0.720 |
Why?
|
| Machine Learning | 1 | 2024 | 330 | 0.700 |
Why?
|
| Intestinal Volvulus | 1 | 2021 | 38 | 0.700 |
Why?
|
| Digestive System Abnormalities | 1 | 2021 | 37 | 0.700 |
Why?
|
| Infant Nutritional Physiological Phenomena | 3 | 2019 | 195 | 0.680 |
Why?
|
| Virus Diseases | 1 | 2023 | 289 | 0.680 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 92 | 0.670 |
Why?
|
| Communicable Diseases | 1 | 2022 | 164 | 0.670 |
Why?
|
| Flavobacteriaceae | 1 | 2020 | 4 | 0.670 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 229 | 0.670 |
Why?
|
| Candida | 3 | 2014 | 83 | 0.660 |
Why?
|
| Hyperoxia | 1 | 2022 | 130 | 0.660 |
Why?
|
| Mycobiome | 1 | 2019 | 9 | 0.660 |
Why?
|
| Metabolome | 2 | 2022 | 312 | 0.650 |
Why?
|
| Staphylococcal Infections | 3 | 2022 | 573 | 0.650 |
Why?
|
| Pregnancy, Twin | 1 | 2021 | 182 | 0.640 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 679 | 0.630 |
Why?
|
| Genomics | 2 | 2025 | 1676 | 0.630 |
Why?
|
| Biomedical Research | 1 | 2025 | 556 | 0.620 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 773 | 0.620 |
Why?
|
| Intestinal Diseases | 1 | 2020 | 87 | 0.620 |
Why?
|
| Intestines | 3 | 2019 | 613 | 0.610 |
Why?
|
| Rotavirus Infections | 2 | 2011 | 357 | 0.590 |
Why?
|
| Patient Isolation | 2 | 2023 | 15 | 0.590 |
Why?
|
| Pneumonia | 1 | 2022 | 342 | 0.590 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 298 | 0.590 |
Why?
|
| Alprostadil | 1 | 2018 | 26 | 0.580 |
Why?
|
| Respiratory System | 1 | 2018 | 100 | 0.570 |
Why?
|
| Morbidity | 4 | 2024 | 255 | 0.570 |
Why?
|
| Zika Virus | 2 | 2016 | 151 | 0.570 |
Why?
|
| Antifungal Agents | 4 | 2013 | 309 | 0.570 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2016 | 253 | 0.550 |
Why?
|
| Oxygen | 1 | 2021 | 577 | 0.550 |
Why?
|
| Neonatology | 1 | 2017 | 57 | 0.550 |
Why?
|
| Preoperative Care | 1 | 2019 | 372 | 0.540 |
Why?
|
| Perinatal Care | 1 | 2017 | 68 | 0.540 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 243 | 0.530 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 262 | 0.530 |
Why?
|
| Polyhydramnios | 2 | 2021 | 56 | 0.520 |
Why?
|
| Pregnancy | 10 | 2024 | 7515 | 0.520 |
Why?
|
| Vasodilator Agents | 1 | 2018 | 213 | 0.510 |
Why?
|
| Ultrasonography | 1 | 2021 | 999 | 0.510 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2021 | 985 | 0.500 |
Why?
|
| Disease Management | 3 | 2019 | 560 | 0.490 |
Why?
|
| Candida albicans | 3 | 2013 | 90 | 0.490 |
Why?
|
| Education | 1 | 2016 | 112 | 0.490 |
Why?
|
| Eye Abnormalities | 1 | 2016 | 105 | 0.490 |
Why?
|
| Coinfection | 2 | 2014 | 183 | 0.480 |
Why?
|
| Infant Formula | 2 | 2019 | 100 | 0.480 |
Why?
|
| Growth | 1 | 2015 | 107 | 0.460 |
Why?
|
| Dietary Supplements | 4 | 2023 | 498 | 0.440 |
Why?
|
| Diet, Protein-Restricted | 1 | 2015 | 82 | 0.430 |
Why?
|
| Deoxycholic Acid | 1 | 2013 | 14 | 0.420 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 1631 | 0.420 |
Why?
|
| Microcephaly | 1 | 2016 | 347 | 0.410 |
Why?
|
| Gestational Age | 5 | 2024 | 1217 | 0.410 |
Why?
|
| Female | 23 | 2024 | 71584 | 0.410 |
Why?
|
| Vasopressins | 1 | 2013 | 45 | 0.410 |
Why?
|
| Amphotericin B | 1 | 2013 | 93 | 0.410 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 290 | 0.410 |
Why?
|
| Dietary Proteins | 1 | 2015 | 255 | 0.410 |
Why?
|
| Candidiasis, Invasive | 1 | 2013 | 23 | 0.410 |
Why?
|
| Feces | 1 | 2017 | 786 | 0.410 |
Why?
|
| Education, Medical | 3 | 2021 | 304 | 0.400 |
Why?
|
| Bias | 2 | 2025 | 147 | 0.390 |
Why?
|
| ROC Curve | 3 | 2024 | 615 | 0.390 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 146 | 0.380 |
Why?
|
| Energy Intake | 1 | 2015 | 519 | 0.380 |
Why?
|
| Farnesol | 1 | 2011 | 4 | 0.380 |
Why?
|
| Leukocyte Transfusion | 1 | 2011 | 7 | 0.380 |
Why?
|
| Hypotension | 1 | 2013 | 191 | 0.360 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2010 | 4 | 0.350 |
Why?
|
| Retrospective Studies | 9 | 2024 | 17456 | 0.340 |
Why?
|
| Education, Distance | 2 | 2021 | 68 | 0.340 |
Why?
|
| Neutropenia | 1 | 2011 | 201 | 0.330 |
Why?
|
| Immunoglobulin M | 2 | 2023 | 224 | 0.320 |
Why?
|
| Reference Standards | 2 | 2021 | 245 | 0.320 |
Why?
|
| Diarrhea | 1 | 2011 | 341 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3843 | 0.310 |
Why?
|
| Numbers Needed To Treat | 2 | 2020 | 3 | 0.310 |
Why?
|
| Asphyxia Neonatorum | 2 | 2016 | 15 | 0.300 |
Why?
|
| Prospective Studies | 5 | 2024 | 6655 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2022 | 341 | 0.300 |
Why?
|
| Lipopolysaccharides | 2 | 2022 | 320 | 0.300 |
Why?
|
| Cause of Death | 3 | 2020 | 502 | 0.290 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2023 | 148 | 0.280 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 1874 | 0.280 |
Why?
|
| DNA | 1 | 2013 | 1675 | 0.280 |
Why?
|
| Mycoses | 2 | 2020 | 121 | 0.280 |
Why?
|
| Child | 7 | 2025 | 25712 | 0.280 |
Why?
|
| Health Personnel | 3 | 2021 | 538 | 0.280 |
Why?
|
| North America | 3 | 2022 | 260 | 0.260 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2020 | 404 | 0.260 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2015 | 319 | 0.260 |
Why?
|
| Fetal Diseases | 1 | 2010 | 462 | 0.260 |
Why?
|
| Epigenomics | 2 | 2025 | 195 | 0.260 |
Why?
|
| Echocardiography | 3 | 2024 | 1111 | 0.250 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 2292 | 0.250 |
Why?
|
| Chronic Disease | 3 | 2020 | 1253 | 0.240 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3738 | 0.230 |
Why?
|
| Bacteria | 2 | 2017 | 534 | 0.230 |
Why?
|
| Maternal Health | 1 | 2024 | 24 | 0.230 |
Why?
|
| Simulation Training | 2 | 2017 | 146 | 0.220 |
Why?
|
| Milk, Human | 3 | 2019 | 310 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1488 | 0.220 |
Why?
|
| Lymphopenia | 1 | 2024 | 39 | 0.220 |
Why?
|
| Fluconazole | 2 | 2008 | 50 | 0.220 |
Why?
|
| Bilirubin | 1 | 2024 | 131 | 0.210 |
Why?
|
| Male | 12 | 2024 | 65815 | 0.210 |
Why?
|
| Prognosis | 2 | 2024 | 5070 | 0.210 |
Why?
|
| Risk Factors | 7 | 2020 | 11077 | 0.210 |
Why?
|
| Length of Stay | 3 | 2019 | 1380 | 0.210 |
Why?
|
| Maternal Exposure | 1 | 2024 | 153 | 0.200 |
Why?
|
| Animals, Newborn | 4 | 2022 | 1045 | 0.200 |
Why?
|
| Fetal Development | 1 | 2024 | 135 | 0.190 |
Why?
|
| Perinatology | 1 | 2022 | 35 | 0.190 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2021 | 82 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 401 | 0.190 |
Why?
|
| Animals | 10 | 2024 | 36363 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2022 | 13011 | 0.190 |
Why?
|
| Metabolomics | 1 | 2025 | 456 | 0.180 |
Why?
|
| Gastroschisis | 1 | 2021 | 55 | 0.180 |
Why?
|
| Femur | 1 | 2021 | 75 | 0.170 |
Why?
|
| Oliguria | 1 | 2000 | 20 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2022 | 284 | 0.170 |
Why?
|
| Proteomics | 1 | 2025 | 592 | 0.170 |
Why?
|
| Waist Circumference | 1 | 2021 | 95 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 754 | 0.170 |
Why?
|
| Interprofessional Relations | 1 | 2022 | 157 | 0.170 |
Why?
|
| Staff Development | 1 | 2020 | 46 | 0.170 |
Why?
|
| Staphylococcaceae | 1 | 2020 | 2 | 0.170 |
Why?
|
| Bradyrhizobium | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hysterotomy | 1 | 2021 | 127 | 0.170 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 4772 | 0.160 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2019 | 23 | 0.160 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2019 | 44 | 0.160 |
Why?
|
| Indomethacin | 1 | 2019 | 86 | 0.160 |
Why?
|
| Computational Biology | 1 | 2025 | 887 | 0.160 |
Why?
|
| Ibuprofen | 1 | 2019 | 43 | 0.160 |
Why?
|
| Intensive Care, Neonatal | 1 | 2019 | 57 | 0.160 |
Why?
|
| Leadership | 1 | 2022 | 245 | 0.160 |
Why?
|
| Time Factors | 4 | 2018 | 6584 | 0.160 |
Why?
|
| Algorithms | 2 | 2024 | 1732 | 0.160 |
Why?
|
| Mice | 5 | 2022 | 18883 | 0.160 |
Why?
|
| Burnout, Professional | 1 | 2021 | 129 | 0.160 |
Why?
|
| Fungi | 1 | 2019 | 76 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2022 | 419 | 0.160 |
Why?
|
| Rats | 3 | 2024 | 3879 | 0.150 |
Why?
|
| Masks | 1 | 2019 | 40 | 0.150 |
Why?
|
| Inflammation | 3 | 2022 | 1595 | 0.150 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 476 | 0.150 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2019 | 145 | 0.150 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2019 | 60 | 0.150 |
Why?
|
| Educational Measurement | 2 | 2020 | 338 | 0.150 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 124 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2022 | 571 | 0.150 |
Why?
|
| Gram-Negative Bacteria | 1 | 2008 | 73 | 0.150 |
Why?
|
| Early Diagnosis | 1 | 2019 | 198 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2008 | 88 | 0.140 |
Why?
|
| Insulin | 1 | 2023 | 1246 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2000 | 249 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2018 | 142 | 0.140 |
Why?
|
| Meningomyelocele | 1 | 2021 | 255 | 0.140 |
Why?
|
| Perinatal Mortality | 1 | 2017 | 44 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 1735 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2024 | 1145 | 0.140 |
Why?
|
| Umbilical Cord | 1 | 2017 | 59 | 0.140 |
Why?
|
| Proteobacteria | 1 | 2017 | 19 | 0.140 |
Why?
|
| Firmicutes | 1 | 2017 | 22 | 0.140 |
Why?
|
| Critical Care | 2 | 2020 | 689 | 0.130 |
Why?
|
| Laryngoscopes | 1 | 2018 | 70 | 0.130 |
Why?
|
| DNA, Fungal | 1 | 2017 | 78 | 0.130 |
Why?
|
| Bacteroides | 1 | 2017 | 37 | 0.130 |
Why?
|
| Clinical Competence | 3 | 2021 | 1066 | 0.130 |
Why?
|
| Fetoscopy | 1 | 2021 | 448 | 0.130 |
Why?
|
| Americas | 1 | 2016 | 51 | 0.130 |
Why?
|
| Incidence | 4 | 2019 | 3393 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 247 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2013 | 827 | 0.130 |
Why?
|
| Brazil | 1 | 2016 | 139 | 0.130 |
Why?
|
| Pandemics | 2 | 2021 | 1196 | 0.120 |
Why?
|
| World Health Organization | 1 | 2016 | 118 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2020 | 1596 | 0.120 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2006 | 151 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 717 | 0.120 |
Why?
|
| Premature Birth | 1 | 2019 | 417 | 0.120 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 497 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 722 | 0.120 |
Why?
|
| Delivery, Obstetric | 1 | 2017 | 258 | 0.120 |
Why?
|
| Hand Hygiene | 1 | 2015 | 18 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1083 | 0.120 |
Why?
|
| Breast Feeding | 1 | 2016 | 243 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 388 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 399 | 0.110 |
Why?
|
| Klebsiella | 1 | 2014 | 11 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2021 | 5173 | 0.110 |
Why?
|
| Staphylococcus | 1 | 2014 | 68 | 0.110 |
Why?
|
| Telemedicine | 1 | 2021 | 496 | 0.110 |
Why?
|
| Developing Countries | 1 | 2016 | 288 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 3050 | 0.110 |
Why?
|
| United States | 4 | 2023 | 11682 | 0.110 |
Why?
|
| Immunity, Innate | 1 | 2016 | 407 | 0.110 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2017 | 453 | 0.110 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2017 | 485 | 0.110 |
Why?
|
| Nucleosides | 1 | 2013 | 19 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2015 | 455 | 0.100 |
Why?
|
| Genotype | 1 | 2019 | 2807 | 0.100 |
Why?
|
| Lypressin | 1 | 2013 | 17 | 0.100 |
Why?
|
| Drug Resistance, Fungal | 1 | 2013 | 30 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 755 | 0.100 |
Why?
|
| Echinocandins | 1 | 2013 | 44 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 83 | 0.100 |
Why?
|
| Europe | 3 | 2021 | 384 | 0.100 |
Why?
|
| Genes, Bacterial | 1 | 2013 | 218 | 0.100 |
Why?
|
| Viral Vaccines | 1 | 2006 | 345 | 0.100 |
Why?
|
| Platelet Activating Factor | 1 | 2012 | 27 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 560 | 0.100 |
Why?
|
| Virulence | 1 | 2013 | 279 | 0.100 |
Why?
|
| Triazoles | 1 | 2013 | 142 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2013 | 283 | 0.100 |
Why?
|
| Curriculum | 1 | 2017 | 777 | 0.100 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2006 | 366 | 0.100 |
Why?
|
| Nafcillin | 1 | 2011 | 14 | 0.100 |
Why?
|
| Nurseries, Hospital | 1 | 2011 | 7 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3987 | 0.090 |
Why?
|
| Colony Count, Microbial | 1 | 2011 | 87 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 91 | 0.090 |
Why?
|
| Virus Shedding | 1 | 2011 | 82 | 0.090 |
Why?
|
| Granulocytes | 1 | 2011 | 70 | 0.090 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 32 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2011 | 239 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 2011 | 128 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2539 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2004 | 311 | 0.090 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 484 | 0.090 |
Why?
|
| Electrolytes | 1 | 2010 | 55 | 0.090 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 179 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2015 | 868 | 0.090 |
Why?
|
| Asia | 2 | 2021 | 127 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 2935 | 0.080 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 371 | 0.080 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 1204 | 0.080 |
Why?
|
| Creatinine | 2 | 2024 | 423 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 406 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1197 | 0.080 |
Why?
|
| Prevalence | 1 | 2016 | 2654 | 0.080 |
Why?
|
| Texas | 2 | 2017 | 3684 | 0.080 |
Why?
|
| Vancomycin | 1 | 2011 | 236 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1334 | 0.080 |
Why?
|
| Pneumococcal Infections | 1 | 2001 | 276 | 0.080 |
Why?
|
| Cytokines | 1 | 2004 | 1396 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2014 | 3638 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2021 | 14776 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1250 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1911 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 2 | 2008 | 390 | 0.060 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 1994 | 53 | 0.050 |
Why?
|
| Adolescent | 1 | 2021 | 20517 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 97 | 0.050 |
Why?
|
| Students, Health Occupations | 1 | 2021 | 4 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2000 | 34 | 0.040 |
Why?
|
| Patient Simulation | 1 | 2021 | 40 | 0.040 |
Why?
|
| Workplace | 1 | 2021 | 82 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 31925 | 0.040 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1993 | 169 | 0.040 |
Why?
|
| New Zealand | 1 | 2020 | 61 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2000 | 134 | 0.040 |
Why?
|
| India | 1 | 2000 | 238 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1485 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 190 | 0.040 |
Why?
|
| Food, Fortified | 1 | 2019 | 98 | 0.040 |
Why?
|
| Milk | 1 | 2019 | 125 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 791 | 0.040 |
Why?
|
| Nonlinear Dynamics | 1 | 2008 | 53 | 0.040 |
Why?
|
| Nose | 1 | 2019 | 98 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2008 | 145 | 0.040 |
Why?
|
| Cattle | 1 | 2019 | 588 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 100 | 0.040 |
Why?
|
| Constriction | 1 | 2017 | 50 | 0.040 |
Why?
|
| Infant Care | 1 | 2017 | 47 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2009 | 184 | 0.040 |
Why?
|
| Placental Circulation | 1 | 2017 | 25 | 0.040 |
Why?
|
| Apgar Score | 1 | 2017 | 50 | 0.030 |
Why?
|
| Hematocrit | 1 | 2017 | 116 | 0.030 |
Why?
|
| Genetic Variation | 1 | 1994 | 1621 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 764 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 1070 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 319 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 309 | 0.030 |
Why?
|
| Manikins | 1 | 2017 | 138 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1667 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 21717 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2007 | 400 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 332 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2017 | 244 | 0.030 |
Why?
|
| Video Recording | 1 | 2017 | 204 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 254 | 0.030 |
Why?
|
| Models, Biological | 1 | 2008 | 1533 | 0.030 |
Why?
|
| Interleukins | 1 | 2004 | 132 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 1067 | 0.020 |
Why?
|
| Steroids | 1 | 2004 | 210 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 317 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 2975 | 0.020 |
Why?
|
| Penicillin Resistance | 1 | 2001 | 81 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2001 | 82 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 707 | 0.020 |
Why?
|
| Vaccination | 1 | 2006 | 1011 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2001 | 172 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 3691 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 815 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 9885 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 450 | 0.020 |
Why?
|
| Nuclear Family | 1 | 1994 | 51 | 0.010 |
Why?
|
| Models, Animal | 1 | 2007 | 483 | 0.010 |
Why?
|
| Weight Gain | 1 | 2007 | 414 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1439 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 29371 | 0.010 |
Why?
|